Literature DB >> 11730972

Evidence for epsilon-opioid receptor-mediated beta-endorphin-induced analgesia.

L F Tseng1.   

Abstract

Among the opioid receptors, which have been pharmacologically classified as mu, delta, kappa and epsilon, the existence of the epsilon receptor has been controversial, and this receptor is generally not recognized as a member of the opioid peptide receptor family because it has not been precisely characterized. However, results from pharmacological, physiological and opioid receptor binding studies clearly indicate the presence of epsilon-opioid receptors, which are distinct from mu-, delta- or kappa-opioid receptors. This putative epsilon-opioid receptor is stimulated supraspinally by the endogenous opioid peptide beta-endorphin, which induces the release of Met-enkephalin, which, in turn, acts on spinal delta2-opioid receptors to produce antinociception. In this article, this beta-endorphin-sensitive epsilon-opioid receptor-mediated descending pain control system, which is distinct from that activated by the mu-opioid receptor agonist morphine, is described and the physiological role of the beta-endorphin-mediated system in pain control activated by cold-water swimming and intraplantar injection of formalin is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11730972     DOI: 10.1016/s0165-6147(00)01843-5

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  10 in total

1.  Influence of endogenous opioid systems on T lymphocytes as assessed by the knockout of mu, delta and kappa opioid receptors.

Authors:  Ali G Karaji; David Reiss; Audrey Matifas; Brigitte L Kieffer; Claire Gavériaux-Ruff
Journal:  J Neuroimmune Pharmacol       Date:  2011-09-22       Impact factor: 4.147

2.  Glycyl-glutamine (beta-endorphin(30-31)) inhibits morphine-induced dopamine efflux in the nucleus accumbens.

Authors:  Nesrin Filiz Basaran; R Levent Buyukuysal; William R Millington; Sinan Cavun
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-27       Impact factor: 3.000

3.  Swim therapy reduces mechanical allodynia and thermal hyperalgesia induced by chronic constriction nerve injury in rats.

Authors:  Jun Shen; Lyle E Fox; Jianguo Cheng
Journal:  Pain Med       Date:  2013-02-25       Impact factor: 3.750

Review 4.  Opioid system and Alzheimer's disease.

Authors:  Zhiyou Cai; Anna Ratka
Journal:  Neuromolecular Med       Date:  2012-04-22       Impact factor: 3.843

5.  Antinociception produced by 14,15-epoxyeicosatrienoic acid is mediated by the activation of beta-endorphin and met-enkephalin in the rat ventrolateral periaqueductal gray.

Authors:  Maia Terashvili; Leon F Tseng; Hsiang-En Wu; Jayashree Narayanan; Lucas M Hart; John R Falck; Phillip F Pratt; David R Harder
Journal:  J Pharmacol Exp Ther       Date:  2008-05-20       Impact factor: 4.030

6.  Synergistic interaction between metformin and sulfonylureas on diclofenac-induced antinociception measured using the formalin test in rats.

Authors:  Mario I Ortiz
Journal:  Pain Res Manag       Date:  2013-08-28       Impact factor: 3.037

Review 7.  Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.

Authors:  Andrea Kurz; Daniel I Sessler
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  The rewarding action of acute cocaine is reduced in β-endorphin deficient but not in μ opioid receptor knockout mice.

Authors:  Alexander T Nguyen; Paul Marquez; Abdul Hamid; Brigitte Kieffer; Theodore C Friedman; Kabirullah Lutfy
Journal:  Eur J Pharmacol       Date:  2012-05-02       Impact factor: 4.432

9.  PMSF Attenuates Morphine Antinociceptive Tolerance and Dependence in Mice: Its Association with the Oxidative Stress Suppression.

Authors:  Ehsan Asadi Akbarabadi; Hossein Rajabi Vardanjani; Shahrzad Molavinia; Marzieh Pashmforoosh; Mohammad Javad Khodayar
Journal:  Iran J Pharm Res       Date:  2021       Impact factor: 1.696

10.  Hypothalamic GPR40 signaling activated by free long chain fatty acids suppresses CFA-induced inflammatory chronic pain.

Authors:  Kazuo Nakamoto; Takashi Nishinaka; Naoya Sato; Mitsumasa Mankura; Yutaka Koyama; Fumiyo Kasuya; Shogo Tokuyama
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.